Skip to main content
European Medicines Agency's logo Go to homepage
Select how you want to search using keywords
  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • Animal health practitioners
    • One Health approach
    • Academia
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Erbitux - withdrawal of application for variation to marketing authorisation

Erbitux - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn

cetuximab
Post-authorisation Human

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Erbitux
  • More information on Erbitux

Overview

On 17 September 2012, Merck KGaA officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Erbitux, to extend its use in the treatment of non-small-cell lung cancer.

Erbitux is an anticancer medicine which has been authorised in the European Union (EU) since 29 June 2004. It is used to treat adults with colorectal cancer (a cancer of the large intestine) when the cancer is metastatic (has spread to other parts of the body). Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain a 'wild-type' (non-mutated) gene called 'KRAS'. In colorectal cancer it can be used in combination with chemotherapy (medicines to treat cancer) or on its own.

Erbitux is also used to treat squamous-cell cancers of the head and neck. In locally advanced cancer (when the tumour has grown but has not spread), Erbitux is given in combination with radiotherapy (treatment with radiation). In cancer that is recurrent (has come back after previous treatment) or metastatic, Erbitux is used with a 'platinum-based' anticancer medicine combination.

Erbitux was also expected to be used to treat advanced or metastatic non-small-cell lung cancer, when the tumour cells have high levels of EGFR on their surface. It was to be used in combination with platinum-based chemotherapy in patients who had not been treated before.

In non-small-cell lung cancer, Erbitux was expected to work in the same way as it does in its existing indications. The active substance in Erbitux, cetuximab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to EGFR, which can be found on the surface of some tumour cells. When it attaches to EGFR, the tumour cells can no longer receive the messages needed for growth, progression and spread.

The applicant presented a re-analysis of the data from one main study involving 1,125 patients with advanced or metastatic non-small-cell lung cancer with EGFR. The study had been previously used to support an application for the use of Erbitux in non-small-cell lung cancers, but this application had been refused. In the study, patients were given cisplatin and vinorelbine (two chemotherapy medicines) with or without Erbitux. The main measure of effectiveness was overall survival (the length of time the patients lived). The company presented an analysis of the study data, comparing the survival of patients whose tumour cells had high levels of EGFR on their surface, with the survival of patients whose tumours had low levels of EGFR.

The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions. After the CHMP had assessed the company's responses to the questions, there were still some unresolved issues.

Based on the review of the data and the company's response to the questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Erbitux could not have been approved for the treatment of non-small-cell lung cancer.

The Committee was concerned that, although the re-analysis of the data indicated that there might be a beneficial effect on survival for patients whose tumour cells had high levels of EGFR, there were some concerns, particularly over the way that patients had been categorised into high- or low-EGFR-level groups in the retrospective analysis, as well as the fact that the effect seen in patients with high EGFR levels in the main study had not been confirmed in another study. Therefore, at the time of the withdrawal, the CHMP concluded that the medicine could not have been approved based on the data presented by the company and that further studies were required to confirm the benefit of Erbitux in patients whose tumour cells have high EGFR levels.

In its official letter, the company stated that its decision to withdraw the application was based on the CHMP's view that the data provided so far are not sufficient to address CHMP's concerns and that more data will be needed.

The letter from the company notifying the Agency of the withdrawal of the application is available under the tab 'All documents'.

The company informed the CHMP that there were no ongoing clinical trials with Erbitux in non-small-cell lung cancer at the time of the withdrawal.

There are no consequences on the use of Erbitux in its authorised indications.

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Erbitux (cetuximab)

Reference Number: EMA/608075/2012

English (EN) (50.95 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View
Other languages (21)

български (BG) (91.38 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

español (ES) (52.15 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

čeština (CS) (80.58 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

dansk (DA) (54.01 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Deutsch (DE) (55.58 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

eesti keel (ET) (51.23 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

ελληνικά (EL) (94 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

français (FR) (52.36 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

italiano (IT) (53.88 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

latviešu valoda (LV) (77.79 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

lietuvių kalba (LT) (79.06 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

magyar (HU) (75.59 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Malti (MT) (79.41 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Nederlands (NL) (53.61 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

polski (PL) (79.63 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

português (PT) (111.17 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

română (RO) (77.91 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

slovenčina (SK) (78.44 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

slovenščina (SL) (75.77 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Suomi (FI) (52.89 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

svenska (SV) (52.13 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Key facts

Name of medicine
Erbitux
EMA product number
EMEA/H/C/000558
Active substance
cetuximab
International non-proprietary name (INN) or common name
cetuximab
Therapeutic area (MeSH)
  • Head and Neck Neoplasms
  • Colorectal Neoplasms
Anatomical therapeutical chemical (ATC) code
L01FE01
Marketing authorisation holder
Merck Europe B.V. 
Date of issue of marketing authorisation valid throughout the European Union
29/06/2004
Date of withdrawal
17/09/2012

Documents

Withdrawal assessment report for Erbitux

Adopted Reference Number: EMA/CHMP/628005/2012

English (EN) (1.6 MB - PDF)

First published: 22/11/2012 Last updated: 22/11/2012
View

Withdrawal letter: Erbitux (cetuximab)

English (EN) (285.31 KB - PDF)

First published: 12/10/2012 Last updated: 12/10/2012
View

Merck KGaA withdraws its application for an extension of the indication for Erbitux (cetuximab)

Reference Number: EMA/607000/2012

English (EN) (54.2 KB - PDF)

First published: 19/09/2012 Last updated: 19/09/2012
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Erbitux

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013
22/11/2013
Merck KGaA withdraws its application for an extension of the indication for Erbitux (cetuximab)
19/09/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 November 2011
18/11/2011
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 November 2009
20/11/2009

More information on Erbitux

  • Erbitux
This page was last updated on 22/11/2012

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
About this website
Languages
Accessibility
Glossaries
Cookies
Website data protection notice
Data protection at EMA
Frequently asked questions
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union